M A Ghannoum1, H G Kim, L Long. 1. Center for Medical Mycology, University Hospitals of Cleveland/Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA. Mahmoud.Ghannoum@case.edu
Abstract
OBJECTIVES: The objective of this study was to compare the activity of aminocandin, a new echinocandin with broad-spectrum activity against Candida spp., with that of amphotericin B, caspofungin and fluconazole, in an immunocompetent murine model of haematogenously disseminated candidiasis caused by a fluconazole-resistant Candida albicans. METHODS: Mice were infected with a fluconazole-resistant strain of C. albicans and treated with aminocandin 5 and 10 mg/kg intravenously (iv) once and twice weekly, amphotericin B 0.5 mg/kg iv every other day for 5 days, fluconazole 20 mg/kg orally (po) once a day for 5 days and caspofungin 0.5 mg/kg intraperitoneally (ip) once daily for 5 days. RESULTS: Treatment with aminocandin, given iv twice a week, resulted in 100% survival. Further, the tissue fungal burden of the aminocandin group was equivalent to that of amphotericin B (administered every other day) and caspofungin (administered daily). CONCLUSIONS: Aminocandin may be an effective addition to the arsenal of antifungal compounds for the treatment of candidiasis caused by fluconazole-resistant C. albicans.
OBJECTIVES: The objective of this study was to compare the activity of aminocandin, a new echinocandin with broad-spectrum activity against Candida spp., with that of amphotericin B, caspofungin and fluconazole, in an immunocompetent murine model of haematogenously disseminated candidiasis caused by a fluconazole-resistant Candida albicans. METHODS:Mice were infected with a fluconazole-resistant strain of C. albicans and treated with aminocandin 5 and 10 mg/kg intravenously (iv) once and twice weekly, amphotericin B 0.5 mg/kg iv every other day for 5 days, fluconazole 20 mg/kg orally (po) once a day for 5 days and caspofungin 0.5 mg/kg intraperitoneally (ip) once daily for 5 days. RESULTS: Treatment with aminocandin, given iv twice a week, resulted in 100% survival. Further, the tissue fungal burden of the aminocandin group was equivalent to that of amphotericin B (administered every other day) and caspofungin (administered daily). CONCLUSIONS:Aminocandin may be an effective addition to the arsenal of antifungal compounds for the treatment of candidiasis caused by fluconazole-resistant C. albicans.
Authors: Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex Journal: Nat Rev Drug Discov Date: 2010-08-20 Impact factor: 84.694
Authors: Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak Journal: Mycoses Date: 2014-10-08 Impact factor: 4.377
Authors: Gabriela E Brzankalski; Laura K Najvar; Nathan P Wiederhold; Rosie Bocanegra; Annette W Fothergill; Michael G Rinaldi; Thomas F Pattterson; John R Graybill Journal: J Antimicrob Chemother Date: 2008-07-25 Impact factor: 5.790